• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Novan, Inc.

    6/21/21 4:45:32 PM ET
    $NOVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NOVN alert in real time by email
    SC 13G 1 tm2120269d1_sc13g.htm SC 13G

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    WASHINGTON, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No.    )*

     

    Novan, Inc. 

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share 

    (Title of Class of Securities)

     

    66988N205 

    (CUSIP Number)

     

    June 11, 2021

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨    Rule 13d-1(b) 

    x   Rule 13d-1(c) 

    ¨    Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 66988N205

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Management, L.P.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)      ¨

    (b)      ¨

     

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

     

    NUMBER OF 5

    SOLE VOTING POWER

     

    0 

    SHARES 

    BENEFICIALLY 

    OWNED BY

    6

    SHARED VOTING POWER

     

    0

    EACH 

    REPORTING 

    PERSON

    7

    SOLE DISPOSITIVE POWER

     

    0 

    WITH: 8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)    ¨

     

     

      

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%1

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA, PN

     

     

     

    1 On June 11, 2021 the reporting person acquired a beneficial ownership of greater than 5%. As of June 21, 2021 the reporting person has a beneficial ownership of 0%.

     

     

     

    CUSIP No. 66988N205

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Peter Kolchinsky

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

    (b)       ¨

     

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America 

     

     

     

    NUMBER OF

    5

    SOLE VOTING POWER

     

    0

    SHARES 

    BENEFICIALLY 

    OWNED BY

    6

    SHARED VOTING POWER

     

    0

    EACH

    REPORTING

    PERSON

    7

    SOLE DISPOSITIVE POWER

     

    0 

    WITH: 8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)    ¨

      

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%2

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, IN

     

     

     

    2 On June 11, 2021 the reporting person acquired a beneficial ownership of greater than 5%. As of June 21, 2021 the reporting person has a beneficial ownership of 0%.

     

     

     

    CUSIP No. 66988N205

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Rajeev Shah

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

    (b)       ¨

     

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America 

     

    NUMBER OF 5

    SOLE VOTING POWER

     

    0 

    SHARES 

    BENEFICIALLY 

    OWNED BY

    6

    SHARED VOTING POWER

     

    0

    EACH 

    REPORTING 

    PERSON

    7

    SOLE DISPOSITIVE POWER

     

    0

    WITH: 8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)    ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%3

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, IN

     

     

     

    3 On June 11, 2021 the reporting person acquired a beneficial ownership of greater than 5%. As of June 21, 2021 the reporting person has a beneficial ownership of 0%.

     

     

     

    CUSIP No. 66988N205

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Healthcare Fund, L.P.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

    (b)       ¨

     

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

     

    NUMBER OF  5

    SOLE VOTING POWER

     

    0 

    SHARES 

    BENEFICIALLY 

    OWNED BY

    6

    SHARED VOTING POWER

     

    0

    EACH 

    REPORTING 

    PERSON

    7

    SOLE DISPOSITIVE POWER

     

    0 

    WITH: 8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)    ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%4

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

     

           

     

    4 On June 11, 2021 the reporting person acquired a beneficial ownership of greater than 5%. As of June 21, 2021 the reporting person has a beneficial ownership of 0%.

     

     

     

    Item 1(a).Name of Issuer:

     

    Novan, Inc. (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    4020 Stirrup Creek Drive, Suite 110 Durham, North Carolina 27703

     

    Item 2(a).Names of Persons Filing:

     

    The names of the persons filing this report (collectively, the “Reporting Persons”) are: 

    RA Capital Management, L.P. (“RA Capital”) 

    Peter Kolchinsky 

    Rajeev Shah 

    RA Capital Healthcare Fund, L.P. (the “Fund”)

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    The address of the principal business office of each of the Reporting Persons is: 

    c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116

     

    Item 2(c).Citizenship:

     

    RA Capital and the Fund are Delaware limited partnerships. Dr. Kolchinsky and Mr. Shah are United States citizens.

     

    Item 2(d).Title of Class of Securities:

     

    Common stock, par value $0.0001 per share (“Common Stock”)

     

    Item 2(e).CUSIP Number:

     

    66988N205

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4.Ownership.

     

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 15,170,715 outstanding Common Stock, as reported in the Issuer’s Form 10-Q filed with the SEC on May 11, 2021 and giving effect to a Reverse Stock Split conversion of every 10 shares to 1 share which occurred on May 25, 2021 as reported in the Issuer’s Form 8-K filed with the SEC on May 25, 2021.

     

     

     

    On June 11, 2021, the Fund acquired a beneficial ownership of the Issuer greater than 5%. As of June 21, 2021, the Fund directly holds 0 shares.

     

    RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the “Act”), of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s portfolio, including the shares of the Issuer’s Common Stock reported herein. Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days’ notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim ownership of the securities reported in this Schedule 13G Statement (the “Statement”) other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of the Statement shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: June 21, 2021  
       
       
    RA CAPITAL MANAGEMENT, L.P.  
       
       
    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Authorized Signatory  
       
    PETER KOLCHINSKY  
       
    /s/ Peter Kolchinsky  
       
    RAJEEV SHAH  
       
    /s/ Rajeev Shah  
       
       
    RA CAPITAL HEALTHCARE FUND, L.P.  
       
    By: RA Capital Healthcare GP, LLC  
         
       
    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Manager  

     

     

     

    EXHIBIT 1

     

    AGREEMENT

     

    This Joint Filing Agreement, dated as of June 21, 2021, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”).

     

    Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G and/or 13D with respect to Common Stock, par value $0.0001 per share of Novan, Inc. beneficially owned by them from time to time.

     

    Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

     

    This Joint Filing Agreement may be terminated by any of the Filers upon one week’s prior written notice or such lesser period of notice as the Filers may mutually agree.

     

    Executed and delivered as of the date first above written.

     

    RA CAPITAL MANAGEMENT, L.P.  
       
       
    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Authorized Signatory  
       
    PETER KOLCHINSKY  
       
    /s/ Peter Kolchinsky  
       
    RAJEEV SHAH  
       
    /s/ Rajeev Shah  
       
       
    RA CAPITAL HEALTHCARE FUND, L.P.  
       
    By: RA Capital Healthcare GP, LLC  
       
    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Manager  

     

     

    Get the next $NOVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NOVN

    DatePrice TargetRatingAnalyst
    9/24/2021$28.00 → $24.00Buy
    HC Wainwright & Co.
    7/9/2021$30.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $NOVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Novan, Inc. (Amendment)

      SC 13D/A - Novan, Inc. (0001467154) (Subject)

      6/24/21 8:19:35 AM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Novan, Inc.

      SC 13G - Novan, Inc. (0001467154) (Subject)

      6/21/21 4:45:32 PM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NOVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ligand Reports Second Quarter 2023 Financial Results

      Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "We are pleased to report continued momentum across our portfolio of partnered assets, with multiple positive developments for our commercial and pipeline products," said Todd Davis, CEO of Ligand. "Ligand has a strong balance sheet with $219 million in cash, and, after a recent paydown of convertible notes, w

      8/8/23 4:01:00 PM ET
      $ALDX
      $GILD
      $JAZZ
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Ligand Offers $15 Million to Acquire Assets of Novan, Inc.

      Ligand provides bridge and debtor-in-possession ("DIP") financing to Novan Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that it has made an offer to acquire the assets of Novan, Inc. (NASDAQ:NOVN) ("Novan") for $15 million in cash and provide up to $15 million in DIP financing to Novan inclusive of a $3 million bridge loan already funded. Novan announced earlier today that it has filed for Chapter 11 reorganization and its entry into a stalking horse acquisition offer with Ligand. The transaction is designed to preserve and maximize the value of Novan's commercial business and berdazimer gel development assets. Berdazimer gel is in development for molluscum contagiosum infe

      7/17/23 8:59:00 AM ET
      $LGND
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection

      – The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan's assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) continues, with Pre-Approval Inspection (PAI) complete and favorable mid-cycle review communication from FDA – – Agreement provides a path forward for a product, if approved, to treat molluscum contagiosum, an unmet medical need – DURHAM, N.C., July 17, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (NASDAQ:NOVN) and its wholly owned subsidiary, EPI Health, LLC (co

      7/17/23 8:45:25 AM ET
      $LGND
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NOVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Sanders Machelle

      4 - Novan, Inc. (0001467154) (Issuer)

      6/27/23 6:30:05 PM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by John A. Donofrio

      4 - Novan, Inc. (0001467154) (Issuer)

      6/8/23 9:22:44 PM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Gay John M.

      4 - Novan, Inc. (0001467154) (Issuer)

      6/8/23 9:22:29 PM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NOVN
    Financials

    Live finance-specific insights

    See more
    • Ligand Reports Second Quarter 2023 Financial Results

      Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "We are pleased to report continued momentum across our portfolio of partnered assets, with multiple positive developments for our commercial and pipeline products," said Todd Davis, CEO of Ligand. "Ligand has a strong balance sheet with $219 million in cash, and, after a recent paydown of convertible notes, w

      8/8/23 4:01:00 PM ET
      $ALDX
      $GILD
      $JAZZ
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Novan to Report First Quarter 2023 Financial Results on May 15, 2023

      DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May 15th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day. The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan management team. Interested participants and investors may access the conference call by dialing (833) 630-1956 (domestic) or (412) 317-1837 (international) and referencing the Novan, Inc. Conference

      5/8/23 9:05:00 AM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand Reports First Quarter 2023 Financial Results

      2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2023 is off to a strong start with $44.0 million in first quarter revenues driven by the continued growth of our royalty revenue and the approval milestone from Travere's FILSPARI for the treatment of IgA nephropathy," said Todd Davis, CEO of Ligand. "We have several partner catalyst

      5/4/23 4:01:00 PM ET
      $ANEB
      $LGND
      $NOVN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NOVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Novan Appoints Brian M. Johnson as Chief Commercial Officer and Receives Conditional FDA Acceptance of Proposed Brand Name KINSOLUS™ for SB206 in Molluscum Contagiosum

      – Mr. Johnson brings broad commercial expertise with over 30 years of leadership spanning dermatology marketing, sales, sales management, digital marketing and managed care –– Company received conditional acceptance from U.S. FDA for use of KINSOLUS™ as brand name for SB206, if approved – – First New Drug Application (NDA) remains on target with submission expected in Q3 2022 – DURHAM, N.C., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced the appointment of Brian M. Johnson as its Chief Commercial Officer. Additionally, the Company received notice that the U.S. Food and Drug Administration (FDA) has conditionally accepted KI

      11/2/21 8:30:00 AM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novan Appoints Tomoko Maeda-Chubachi, MD, PhD, MBA as Chief Medical Officer

      – Dr. Maeda-Chubachi, who served as Novan's Senior Vice President, Medical has played a key role in the design and execution of the Company's development programs – – Dr. Maeda-Chubachi was instrumental in the execution of B-SIMPLE4, the Company's pivotal Phase 3 trial of SB206 in molluscum contagiosum, which recently reported positive topline efficacy and safety results – – Additionally, the Company announces Dr. Maeda-Chubachi's publication in JID Innovations based on previously completed Phase 3 studies (B-SIMPLE1 and B-SIMPLE2) suggesting SB206 may trigger the beginning-of-the-end ("BOTE") inflammation and shorten the duration of molluscum infection – DURHAM, N.C., Aug. 24, 2021 (GL

      8/24/21 9:00:00 AM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pritzker Private Capital Appoints Paula Brown Stafford to Pritzker Advisory Board

      Pharmaceutical Services Leader Strengthens PPC's Capabilities and Enhances Strategic Initiative to Invest in Market-Leading Healthcare Companies Pritzker Private Capital ("PPC"), a leader in family direct investing, today announced the appointment of Paula Brown Stafford to the Pritzker Advisory Board. Ms. Stafford, currently Chairman and CEO of biotechnology company Novan, brings more than 30 years of healthcare industry experience to the Pritzker Advisory Board and PPC's family of companies. Her appointment will enhance PPC's initiatives to invest in and partner with market-leading healthcare companies, specifically in healthcare services, medical products, pharmaceutical services and th

      7/20/21 8:00:00 AM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NOVN
    SEC Filings

    See more
    • Novan Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Material Modification to Rights of Security Holders

      8-K - NVN Liquidation, Inc. (0001467154) (Filer)

      1/30/24 4:47:37 PM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novan Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - NVN Liquidation, Inc. (0001467154) (Filer)

      1/26/24 4:38:13 PM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novan Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - NVN Liquidation, Inc. (0001467154) (Filer)

      12/21/23 4:13:26 PM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NOVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Novan with a new price target

      HC Wainwright & Co. reiterated coverage of Novan with a rating of Buy and set a new price target of $24.00 from $28.00 previously

      9/24/21 6:07:00 AM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Novan with a new price target

      Cantor Fitzgerald initiated coverage of Novan with a rating of Overweight and set a new price target of $30.00

      7/9/21 6:35:54 AM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Novan with a new price target

      HC Wainwright & Co. reiterated coverage of Novan with a rating of Buy and set a new price target of $28.00 from $20.00 previously

      6/14/21 6:19:32 AM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care